{"id":"W4362586968","doi":"10.1016/s1556-0864(23)00338-6","title":"84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Genentech; F-star Therapeutics; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; G1 Therapeutics; Amgen; LUNGevity Foundation; Mesothelioma Applied Research Foundation","keywords":"Medicine; Internal medicine; Oncology; Complete response; Neoadjuvant therapy; Nivolumab; Gastroenterology; Chemotherapy; Surgery; Cancer; Breast cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001265625,0.0003899349,0.001362881,0.0006851096,0.0002635781,0.001147817,0.0007707753,0.0006954721,0.002542538],"category_scores_gemma":[0.002955059,0.0002690325,0.00135338,0.0006698552,0.0002767042,0.001215993,0.0005204706,0.001751956,0.001108913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001372263,"about_ca_system_score_gemma":0.001305062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002645725,"about_ca_topic_score_gemma":0.01063888,"domain_scores_codex":[0.999715,0.00005388327,0.00005428745,0.00005357843,0.00007293536,0.000050238],"domain_scores_gemma":[0.9986307,0.000608401,0.0002015176,0.00005936246,0.0003135988,0.0001863578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.001831413,0.000164564,0.01022887,0.002145043,0.0004618684,0.0003978059,0.00006144166,0.0008055186,0.002591093,0.0006433277,0.06540021,0.9152688],"study_design_scores_gemma":[0.002184566,0.003570486,0.0621999,0.00615616,0.002737321,0.006256992,0.0001305982,0.001636043,0.003364535,0.001753399,0.9098924,0.0001176681],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.05416404,0.885478,0.003146823,0.02425871,0.005455508,0.0002200507,0.003088659,0.0004280603,0.02376009],"genre_scores_gemma":[0.18668,0.7228567,0.009088979,0.05045798,0.00784631,0.0004295578,0.009389079,0.0003531579,0.0128983],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.002645725,"threshold_uncertainty_score":0.009956539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0344534782357647,"score_gpt":0.4077052869778547,"score_spread":0.37325180874209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}